Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?

Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment.

Detalles Bibliográficos
Autores principales: Avcilar, Huseyin, Eken, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434307/
https://www.ncbi.nlm.nih.gov/pubmed/33254510
http://dx.doi.org/10.1016/j.mehy.2020.110202
_version_ 1783572118366060544
author Avcilar, Huseyin
Eken, Ahmet
author_facet Avcilar, Huseyin
Eken, Ahmet
author_sort Avcilar, Huseyin
collection PubMed
description Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment.
format Online
Article
Text
id pubmed-7434307
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-74343072020-08-19 Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19? Avcilar, Huseyin Eken, Ahmet Med Hypotheses Article Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment. Elsevier Ltd. 2020-11 2020-08-18 /pmc/articles/PMC7434307/ /pubmed/33254510 http://dx.doi.org/10.1016/j.mehy.2020.110202 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Avcilar, Huseyin
Eken, Ahmet
Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
title Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
title_full Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
title_fullStr Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
title_full_unstemmed Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
title_short Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
title_sort could imiquimod (aldara 5% cream) or other tlr7 agonists be used in the treatment of covid-19?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434307/
https://www.ncbi.nlm.nih.gov/pubmed/33254510
http://dx.doi.org/10.1016/j.mehy.2020.110202
work_keys_str_mv AT avcilarhuseyin couldimiquimodaldara5creamorothertlr7agonistsbeusedinthetreatmentofcovid19
AT ekenahmet couldimiquimodaldara5creamorothertlr7agonistsbeusedinthetreatmentofcovid19

Ejemplares similares